Eris Lifesciences has bolstered its position in pharmaceutical manufacturing by acquiring a 30% stake in Swiss Parenterals Ltd for ₹4.23 billion. The investment marks Eris’s strategic entry into the rapidly growing parenteral drug market.
Swiss Parenterals manufactures a diverse portfolio of injectable and infusion products for both domestic and international markets. Eris noted that this stake purchase will deepen its presence in parenteral formulations, especially as demand for specialised and high-quality manufacturing capabilities continues to rise.
